Circassia has announced the US Food and Drug Administration (FDA) approval of its chronic obstructive pulmonary disease (COPD) maintenance treatment, Duaklir.
UK biotech Circassia has said that its partner AIT Therapeutics has held a meeting with the FDA that paves the way for premarket approval of its nitric oxide product for newborn babies with respiratory failure, AirNOvent.
Four years ago, Circassia looked to have ushered in a new era for biotech IPOs on the London Stock Exchange when it raised £200 million ($252 million) to.....
The firm already promotes the COPD therapy in the US under a profit share arrangement covering the drug and fellow COPD therapy Duaklir (aclidinium/formoterol), established by the two companies in April last year.